Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old
2024; Elsevier BV; Volume: 22; Linguagem: Inglês
10.1016/j.jvacx.2024.100595
ISSN2590-1362
AutoresDagmar García-Rivera, Rinaldo Puga-Gómez, Sonsire Fernández-Castillo, Beatriz Paredes-Moreno, Yariset Ricardo-Delgado, Meiby Rodríguez-González, Carmen Valenzuela Silva, Rocmira Pérez-Nicado, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanet Climent-Ruíz, Enrique Noa-Romero, Otto Cruz-Sui, Belinda Sánchez-Ramírez, Tays Hernández-García, Ariel Palenzuela-Díaz, Marisel Martínez-Pérez, Arilia García-López, Yury Valdés-Balbín, Vicente Vérez-Bencomo,
Tópico(s)Heparin-Induced Thrombocytopenia and Thrombosis
Referência(s)